Glucocorticoids amplify glomerular injury in rats with renal ablation
- PMID: 3370134
- DOI: 10.1093/ajh/1.1.54
Glucocorticoids amplify glomerular injury in rats with renal ablation
Abstract
Male Munich-Wistar rats were subjected to 1 2/3 nephrectomy. One group received no therapy (C). A second group received daily doses of methylprednisolone (MP). A third group received MP plus the angiotensin I converting enzyme inhibitor (CEI) benzazepril. A fourth group received CEI alone. Half of the rats in each group underwent micropuncture study 2 weeks after ablation. Untreated rats exhibited systemic hypertension and elevation of the single nephron glomerular filtration rate (SNGFR), due to glomerular capillary hyperperfusion and hypertension. Administration of MP resulted in comparable systemic hypertension with further elevation of SNGFR due to even higher values for glomerular perfusion and hydraulic pressure (PGC). Concurrent treatment with CEI-controlled systemic and glomerular hypertension despite equivalent renal ablation and comparable doses of MP. After 12 weeks untreated rats demonstrated continued systemic hypertension, progressive proteinuria, and eventual glomerular sclerosis. Addition of MP dramatically accelerated the development of proteinuria and glomerular sclerosis, while CEI afforded striking protection against disease progression. Thus, potent vasodilator glucocorticoids may amplify hemodynamically mediated glomerular injury, whereas control of systemic and glomerular hypertension prevents this undesirable consequence of chronic steroid therapy.
Similar articles
-
Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation.J Clin Invest. 1987 Sep;80(3):867-74. doi: 10.1172/JCI113145. J Clin Invest. 1987. PMID: 3040810 Free PMC article.
-
Therapeutic implications of converting-enzyme inhibitors in renal disease.Am J Kidney Dis. 1987 Jul;10(1 Suppl 1):81-7. Am J Kidney Dis. 1987. PMID: 3037894
-
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.J Clin Invest. 1986 Jun;77(6):1993-2000. doi: 10.1172/JCI112528. J Clin Invest. 1986. PMID: 3011863 Free PMC article.
-
Antihypertensive therapy must control glomerular hypertension to limit glomerular injury.J Hypertens Suppl. 1986 Dec;4(5):S242-4. J Hypertens Suppl. 1986. PMID: 3553475 Review.
-
Reversing glomerular hypertension stabilizes established glomerular injury in renal ablation.J Hypertens Suppl. 1986 Dec;4(5):S239-41. J Hypertens Suppl. 1986. PMID: 3033177 Review.
Cited by
-
Protection of Renal Function with ACE Inhibitors: Experience with Benazepril.Clin Drug Investig. 1998;16(6):463-72. doi: 10.2165/00044011-199816060-00006. Clin Drug Investig. 1998. PMID: 18370561
-
Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.Drugs. 1991 Sep;42(3):511-39. doi: 10.2165/00003495-199142030-00008. Drugs. 1991. PMID: 1720384 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources